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Pathogenesis of vascular calcification in chronic kidney disease.
Background. Hyperphosphatemia and hypercalcemia are in-
dependent risk factors for higher incidence of cardiovascular
events in patients with chronic kidney disease. In addition to in-
creased calcium-phosphate product, hyperphosphatemia accel-
erates the progression of secondary hyperparathyroidism with
the concomitant bone loss, possibly linked to vascular calcium-
phosphate precipitation.
Results. The control of serum phosphate levels reduces vascu-
lar calcification not only by decreasing the degree of secondary
hyperparathyroidism and calcium-phosphate product, but also
by reducing the expression of proteins responsible for active
bone mineral deposition in cells of the vasculature. The calcium
and aluminum-free phosphate-binders provide a new and ef-
fective therapeutic tool in preventing vascular calcifications in
chronic kidney disease in animal models and in hemodialysis
patients.
Conclusion. Additional investigations are necessary to ex-
amine the benefits of different phosphate-binders in reducing
mortality from cardiovascular disease.
Cardiovascular events are the most frequent cause of
death in patients with chronic renal failure [1, 2]. Cal-
cification of soft tissues and blood vessel walls occurs
more frequently in dialyzed patients compared to the
nonuremic population [3–5].
In the last decade, large evidence has been accu-
mulated indicating that disturbances in mineral and
bone metabolism in patients with chronic kidney disease
(CKD) associate with vascular calcification and increased
morbidity and mortality. Abnormalities in mineral and
bone metabolism are very common in end-stage renal
disease (ESRD). In this patient population, parathyroid
gland enlargement and high circulating levels of parathy-
roid hormone (PTH) are major contributors to increased
bone resorption, a feature of renal osteodystrophy [6, 7].
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Thus, vascular calcification is linked to enhanced bone re-
sorption. In addition, an inverse relationship between ar-
terial calcification and bone density has been documented
in uremic patients [8]. In the general population there is
an association between osteoporosis and vascular calcifi-
cation [9].
Recently [10], a multivariate analysis performed in a
group of patients maintained on hemodialysis demon-
strated that the arterial calcification score was positively
associated with age and daily dose of calcium-containing
phosphate binders, and an inverse correlation with os-
teoblastic surfaces. A high arterial calcification score was
associated with bone histomorphometry suggestive of
low bone activity and adynamic bone disease. Thus, an
oversuppression of PTH could also influence the devel-
opment of vascular calcification.
Vascular calcification involves not only passive
calcium-phosphate deposition on atherosclerotic vessels
but active “ossification” of vascular structures [11, 12].
Hyperphosphatemia and increased calcium-phosphate
product are important contributors to vascular calci-
fications in uremic patients, and also appear to be
associated with increased mortality [13, 14]. In partic-
ular, elevated blood levels of phosphate associate with
ectopic calcifications and increased risk of calciphylaxis
[8, 15–17]. Unfortunately, the pathogenic mechanisms
for hyperphosphatemia, high calcium-phosphate prod-
uct, secondary hyperparathyroidism, or kidney disease
in itself in enhancing vascular calcification in CKD are
still incompletely understood. Because vascular calcifica-
tions cause higher morbidity and mortality, the control
of serum phosphate in patients with CKD is crucial in
preventing increases in calcium-phosphate product, sec-
ondary hyperparathyroidism and, therefore, ectopic cal-
cifications [18]. In the past, the standard treatment for the
hyperphosphatemia of CKD consisted of dietary phos-
phate restriction, efficient dialysis treatment, and admin-
istration of phosphate-binders (aluminum salts, calcium
carbonate, or acetate). Recent studies proved the limi-
tations of calcium salts as phosphate-binders elevating
calcium load in patients with ESRD [19, 20], and with
more than 50% of patients not achieving a good control
of serum phosphate levels [13, 14].
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Table 1. Opposite effects of proteins associated with vascular
calcification
Inhibitory genes Inducing genes
Osteopontin (OPN) Alkaline phosphatase (ALP)
Matrix Gla-protein (MGP) Osteocalcin (OC)
Fetuin (Ahsg) Osteonectin (ON)
Osteoprotegerin (OPG) Bone matrix protein 2a (BMP 2a)
The development of new phosphate binders that do not
contain aluminum or calcium opened new perspectives in
preventing vascular calcifications in ESRD in animals and
humans [20, 21].
This review presents the current understanding of
pathogenic mechanisms for regulation and prevention of
ectopic calcification in CKD.
PROTEINS MODULATING ECTOPIC
CALCIFICATIONS
In the last decade, several studies have defined cal-
cification of atherosclerotic lesions as an active process
similar to bone formation. Different gene products seem
to induce or inhibit the process of ectopic calcification
(Table 1). In particular, matrix Gla-protein, fetuin, osteo-
protegerin, and osteopontin may play a very important
role on inhibiting mineral deposition in the vasculature.
In fact, these 4 “protective” proteins associate with re-
duced vascular calcification and may be the regulatory
keys in preventing ectopic calcification in renal failure.
Matrix gla-protein (MGP)
During the first 8 weeks of life, mice lacking MGP de-
velop osteoporosis and pathologic fractures, as well as
diffuse arterial calcification [22]. In addition, MGP is an
extracellular matrix protein with high affinity for hydrox-
yapatite that actively participates in the pathophysiology
of osteoporosis and in the prevention of vascular calcifi-
cation [23]. These data indicate that MGP is required to
both promote normal bone formation and inhibit vascu-
lar calcification, but its potential role in CKD still needs
to be clarified.
Fetuin (Ahsg)
a2-Heremans-Schmid glycoprotein (Ahsg), also
known as fetuin-A, is an important inhibitor of ectopic
calcification. Serum concentrations of fetuin fall during
the cellular immunity-phase of inflammation [24, 25].
In vitro, fetuin inhibits the de novo formation and
precipitation of calcium-phosphate, with no effects on
hydroxyapatite once it is formed [26, 27]. Ahsg-deficient
mice develop extensive soft tissue calcifications in my-
ocardium, kidney, lung, tongue, and skin [28]. Recently,
Ketteler et al [29] reported that low serum fetuin levels
associate with increased cardiovascular mortality in
patients receiving hemodialysis treatment, therefore
suggesting that Ahsg could be involved in preventing the
accelerated extraskeletal calcification observed in CKD.
Fetuin/MGP complex
In the last 5 years, Price et al [30–33] characterized
biochemically and physiologically a high-molecular-mass
complex of bone calcium-phosphate mineral and serum
fetuin, matrix Gla protein (MGP), and a new 24-kD pro-
tein (spp 24), similar to fetuin and MGP [32]. This high-
molecular-mass complex inhibits bone mineralization in
vivo [30–32].
Paradoxically, in studies stimulating bone resorption
with pharmacologic doses of vitamin D [33], formation
of fetuin-mineral complex coincides temporally with in-
creases in bone resorptive activity and arterial calcifica-
tions. Furthermore, there is a reduction in serum fetuin in
rats with ongoing artery calcification. It is possible that ex-
cessive bone resorption generates such massive amounts
of fetuin mineral complex that impair fetuin ability to fur-
ther arrest the growth of the mineral components, which
could then induce arterial calcifications. The reduction
in serum fetuin associates with clearance of the complex
from circulation. In fact, when bone resorption is pre-
vented through administration of biphosphonates, there
is no reduction of serum fetuin. The striking correlation
between depletion of serum fetuin and death suggests
that exhaustion of serum fetuin is an important patho-
physiologic factor [33].
Osteoprotegerin (OPG)
Bucay et al [34] showed low bone density and increased
arterial calcification in OPG-deficient mice. Similar to
matrix Gla-protein and fetuin, osteoprotegerin appears
to inhibit ectopic calcification, playing an important role
in both pathologic and physiologic calcification processes
[35].
Osteopontin (OPN)
Recently, several authors [36, 37] proposed that OPN
acts as an inhibitor of calcification of vascular smooth
muscle cell (VSMC) cultures, while Jono et al [38] demon-
strated that the phosphorylation of osteopontin was a
mandatory step to inhibit VSMC calcification. Thus, os-
teopontin is both an important modulator of bone miner-
alization and a potent inhibitor of ectopic calcifications.
In contrast to the protective effects of matrix Gla-
protein, fetuin, osteoprotegerin, and osteopontin, a
higher expression of osteocalcin, alkaline phosphatase
[39], osteonectin [40], and BMP2a [41] was associated
with myofibroblasts and vascular smooth muscle cells be-
ing diverted to the osteogenic lineage with a concomitant
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induction of calcification (Table 1). More studies are nec-
essary to clarify the impact of altered expression and func-
tion of these gene products in the vascular calcification
of end-stage kidney disease.
INDUCTION OF VASCULAR CALCIFICATION
BY HIGH PHOSPHATE LEVELS AND UREMIC
TOXINS
In the last 10 years, several mechanisms have been pro-
posed for phosphate regulation of vascular calcification,
involving not only deposition of calcium and phosphate in
the vasculature, but also direct activation of genes associ-
ated with osteoblastic functions in vascular smooth mus-
cle cells [11]. Jono and Giachelli [42, 43] showed that high
phosphorus levels in the incubation media (2 mmol/L) en-
hanced calcification in human aortic smooth muscle cells
(HSMCs). Phosphate-containing mineral deposition was
predominant in the extracellular matrix [42].
In vivo studies by Kuro-o et al [44] demonstrated that
even in the presence of normal renal function, a 2-fold in-
crease in serum phosphate levels in the KLOTHO-gene
mutant mice resulted in increased calcium-phosphate
product with the development of vascular calcifications
and osteoporosis.
Characterization of the mechanisms involved in phos-
phate induction of calcification, in in vitro studies,
indicated that high phosphate increased HSMCs calcifi-
cation is dependent upon a functional sodium-phosphate
cotransporter Pit-1, and involves direct induction of the
osteoblast-specific genes Osf2/Cbfa-1 [45]. Moreover,
Cbfa-1 regulates the expression of osteocalcin [46], one
of the most important genes in osteoblastogenesis. Also,
in bovine vascular smooth muscle cells (BVSMCs) in-
cubated with different concentration of phosphate, the
expression of osteopontin and alkaline phosphatase in-
creases, and calcification is induced [47].
Importantly for CKD, in BVSMCs, the expression of
these proteins critical in bone formation was also induced
by uremic serum independently of phosphate concentra-
tions [47]. This finding constitutes the first demonstration
of direct induction of vascular calcification by uremic tox-
ins in vitro. Interestingly, changes in phosphate had no
further effect on calcification. Of significance was the re-
port by Moe at al [48], demonstrating increased expres-
sion of the key transcriptional regulator of osteoblasts
differentiation, Osf2/Cbfa1, and osteopontin in the me-
dia and intima of calcified epigastric arteries from uremic
patients.
Recent studies [49, 50] have demonstrated the role of
calcium, per se, in addition to phosphate in the devel-
opment of vascular calcification in HVSMCs. Yang et al
[49] described that elevated calcium stimulated miner-
alization of HSMC under normal phosphate conditions,
and accelerated mineralization under elevated phosphate
Hyperphosphatemia
hypercalcemia
Calcium-phosphate
deposition
Vascular
calcification
Bone associated
genes
Fig. 1. Role of phosphate and calcium on vascular calcification in CKD.
Hyperphosphatemia and hypercalcemia increase calcium and phos-
phate deposition in the vasculature through two different mechanisms:
a passive one involving calcium-phosphate precipitation in the vascula-
ture, and an active one that induces the expression of bone associated
genes in vascular smooth muscle cells, which acquire the phenotype of
bone forming (osteoblast-like) cells.
conditions. The elevated calcium induced the expression
of the sodium-dependent phosphate cotransporter, Pit-1.
Calcium-induced mineralization was inhibited by phos-
phonoformic acid (FPA), an inhibitor of the sodium-
dependent phosphate cotransporter, in a manner similar
to FPA inhibition of phosphate-induced mineralization.
This indicates that calcium-induced mineralization was
also dependent on the activity of a sodium-dependent
phosphate cotransporter. In addition, elevated calcium
increased mRNA levels of Cbfa-1 and alkaline phos-
phatase similar to those observed in elevated phosphate-
treated HVSMC. Reynolds et al [50] demonstrated that
elevated calcium or phosphate induced HVCMC cal-
cification independently and synergistically, a process
that was inhibited by normal serum. The investigators
found that in the presence of increased phosphate, even
a modest increase in calcium can significantly exacerbate
calcification. This process is induced by nucleation of ba-
sic calcium phosphate in vesicles that are released from
both viable and apoptotic HVSMC. Taken together, the
results of these investigations [49, 50] suggest that the
abnormal vascular calcification observed in patients with
CKD results from reduced capacity of HVSMC to inhibit
mineralization via cell-mediated mechanisms.
These in vivo and in vitro findings support a new defini-
tion of arterial calcification as an active process, “similar”
to bone formation, and suggest that serum phosphate and
calcium levels, as well as the uremic state, per se, could di-
rectly regulate vascular calcification through modulation
of the expression of proteins with bone-forming activity
in the vessel walls (Fig. 1).
PREVENTION OF THE DETERIORATION OF
RENAL FUNCTION AND KIDNEY
CALCIFICATION BY CONTROLLING SERUM
PHOSPHATE IN EXPERIMENTAL KIDNEY
DISEASE
In 1978, Ibels et al [51] described that in 5/6 nephrec-
tomized rats, dietary phosphate restriction associated
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with preservation of renal function. Two years later, the
renal toxicity of phosphate in rats was elucidated [52].
Chronic kidney disease causes a reduction in the num-
ber of nephrons and consequently in phosphate excre-
tion; different studies have shown that phosphate reten-
tion not only induces secondary hyperparathyroidism,
but also accelerates renal failure by inducing kidney calci-
fications [53]. In more than 200 renal biopsies in humans,
Gimenez et al [54] showed a correlation between high
blood phosphate levels, renal calcium deposition, and the
progression of renal failure. In these studies, patients with
higher serum calcium-phosphate product, renal calcium
content, and histologic calcium deposition were those
with serum creatinine levels above 1.5 mg/dL [54]. In ex-
perimental renal failure, the accelerated deterioration of
renal function induced by high dietary phosphate asso-
ciates with nephrocalcinosis, as depicted by renal calcium-
phosphate precipitation and tubulointerstitial damage
[55].
In 1980, Walser [56] described the association between
calcium salt (calcium carbonate) administration to ESRD
patients and elevated serum creatinine concentration af-
ter 2 to 4 weeks of treatment. More recently, Hsu et al
[57] pointed out that dialysis patients are in a positive cal-
cium balance, and that the excess calcium is present in soft
tissues. In addition, there is evidence that calcium deposi-
tion in dialysis patients may be triggered by inflammation
[58].
The control of serum calcium-phosphate product is
critical in preventing ectopic calcification in chronic
renal failure. Recently, Nagano et al [59, 60] exam-
ined whether sevelamer hydrochloride, a noncalcemic
phosphate-binder, could slow deterioration of renal
function in rats with progressive renal insufficiency.
In sevelamer-treated rats, serum phosphorus, calcium-
phosphorus product, and PTH levels were greatly de-
creased compared to untreated animals. Sevelamer not
only prevented the decrease in creatinine clearance and
elevations in kidney calcium content, but also reduced
glomerular and tubulointerstitial histologic lesions of the
kidney [60].
Using the 5/6 nephrectomy model of CKD in rats, we
compared the effects of sevelamer and calcium carbon-
ate in the control of serum phosphate, secondary hyper-
parathyroidism, and kidney calcifications [61]. Sevelamer
was as effective as calcium carbonate in reducing serum
phosphate and PTH levels, and in controlling parathyroid
gland growth. Moreover, sevelamer treatment controlled
serum phosphate independent of increases in serum cal-
cium, thus reducing serum calcium-phosphate product,
and preventing further deterioration of renal function
(Fig. 2). Sevelamer-treated rats showed reduced renal cal-
cium deposition compared to untreated uremic animals
or rats taking calcium carbonate as phosphate-binder. Im-
portantly, the degree of tubular-interstitial fibrosis was
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Fig. 2. Prevention of renal function deterioration in long-term exper-
imental renal failure. Relative potencies of CaCO3 and sevelamer in
preventing the increases in serum creatinine, decreases in creatinine
clearance, and urinary protein excretion compared to untreated uremic
controls, 6 months after the onset of renal failure.
also markedly lower when rats were treated with seve-
lamer [61].
Both studies provide enough evidence that in experi-
mental chronic renal failure in rats, sevelamer not only
reduces serum phosphate and PTH levels but prevents
kidney calcium deposition and tubulointerstitial fibrosis,
thus preserving renal function.
PREVENTION OF CARDIOVASCULAR
CALCIFICATION IN EXPERIMENTAL KIDNEY
DISEASE
In chronic kidney disease, severe complications, includ-
ing secondary hyperparathyroidism, ectopic calcification,
and increased cardiovascular morbidity and mortality are
associated with increased serum phosphate levels [13, 14].
Therefore, prevention of vascular calcification through a
strict control of phosphate and calcium-phosphate prod-
uct is a major goal for new therapeutic agents.
Recently, 2 studies examined the efficacy of sevelamer
in preventing ectopic calcification of soft tissues in ex-
perimental renal failure. In rats with adenine-induced
renal failure, Katsumata et al [62] showed that serum
phosphate, calcium-phosphate product, and PTH levels
were reduced by treatment with sevelamer compared
with the untreated uremic animals. More importantly,
therapy with sevelamer was accompanied by reduced
aortic calcification and ameliorated renal osteodystro-
phy in this animal model [62]. In addition, in our study
using the 5/6 nephrectomized model in rats, treatment
for 6 months with either calcium carbonate or sevelamer
demonstrated that the phosphate-binder sevelamer
controls serum phosphate and secondary hyperparathy-
roidism as well as calcium salts, but greatly attenuates
vascular calcification and, as mentioned earlier, the de-
terioration of kidney function (Fig. 3) [63]. Despite
the similar efficacy of sevelamer and calcium carbon-
ate to maintain serum levels of serum phosphorus,
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Fig. 3. Prevention of kidney, myocardium, and aorta calcification in
long-term experimental chronic renal failure. Relative potencies of
CaCO3 and sevelamer in controlling kidney, myocardium, and aorta
calcification compared to untreated uremic controls, 6 months after the
onset of renal failure.
calcium-phosphate product, and PTH, less ectopic calci-
fications within the myocardium, aorta, and kidney were
found in the sevelamer treated group of uremic animals
[63]. Sevelamer also induced less deterioration in renal
function, as indicated by higher creatinine clearance and
lower urinary protein excretion.
Many factors, including high phosphate, calcium, and
vitamin D therapy are associated with the development
of vascular calcification. In the treatment of secondary
hyperparathyroidism, 1,25(OH)2D3 has been used be-
cause of its efficacy in suppressing PTH synthesis and
secretion through a mechanism similar to other steroid
hormones, which involves its receptor, the vitamin D
receptor [6, 64, 65]. However, the hypercalcemia and
hyperphosphatemia that results from increased intesti-
nal calcium and phosphate absorption or bone resorp-
tion often precludes the therapeutic use of 1,25(OH)2D3
in chronic kidney disease patients. Because of the po-
tent effects of 1,25(OH)2D3 in increasing intestinal
calcium absorption, and calcium and phosphate mobi-
lization from bone, vitamin D therapy further increases
the risk of development of soft tissue calcification in
patients with an already enhanced calcium-phosphate
product, especially in those receiving calcium salts
as phosphate binders [15]. As a result, analogues of
1,25(OH)2D3 that suppress PTH synthesis and secretion
in uremic rats with secondary hyperparathyroidism at
doses that do not increase either serum calcium or phos-
phate levels were developed [66, 67]. The mechanisms re-
sponsible for the decreased calcemic and phosphatemic
activities of these new 1,25(OH)2D3 analogues are in-
completely elucidated.
A recent study by Hirata et al [68] compared the effi-
cacy of 22-oxacalcitriol (OCT), a 1,25(OH)2D3 analogue
with lesser calcemic activity than 1,25(OH)2D3, in sup-
pressing secondary hyperparathyroidism and soft tissue
calcifications in 5/6 nephrectomized rats. Despite a similar
control of serum PTH levels, kidney, myocardial, and aor-
Table 2. Risk factors for cardiovascular disease in chronic renal
failure patients
Classic Nonclassic
Hypertension ↑Advanced glycation end products (AGEs)
Diabetes ↑Oxidative stress and nitric oxide (NO)
Dyslipidemia ↑Asymetric dimethylarginine (ADMA)
Obesity ↑Homocysteine
Smoking ↑Phosphate and calcium-phosphate product
Gender
Family history
tic calcifications were more severe in the 1,25(OH)2D3-
treated group than in the animals receiving OCT. In ad-
dition, the deterioration of the residual renal function,
tubular-interstitial changes, and nephrocalcinosis were
significantly lower in OCT-treated rats compared to ani-
mals receiving 1,25(OH)2D3 [68].
More importantly, a 16% survival advantage was re-
cently reported in a retrospective study of over 60,000
chronic hemodialysis patients throughout the United
States treated with the vitamin D analogue paricalci-
tol compared to those treated with calcitriol [69]. This
report demands validation from controlled prospective
studies. Several mechanisms could contribute to the sur-
vival advantage of paricalcitol. In addition to the milder
elevations in serum phosphate and calcium levels with
analogue therapy compared to those induced by cal-
citriol, there could be a higher potency of paricalcitol to
display nonclassic calcitriol actions, such as in the down-
regulation of the renin-angiotensin system [70], or in the
inhibition of smooth muscle proliferation [71]. The ac-
tual role of these processes in vascular calcification is only
speculative at present.
NONCLASSIC CARDIOVASCULAR RISK
FACTORS IN CKD PATIENTS
Patients with chronic renal failure develop atheroscle-
rotic vascular disease more frequently and earlier than
the general population [4, 5]. Several elements need
to be added to the classic risk factors, such as hyper-
tension, diabetes, dyslipidemia, obesity, gender, smok-
ing, and family history, in uremia-induced cardiovascular
disease. In particular, advanced-glycation end products
(AGEs), oxidative stress, and nitric oxide (NO), asym-
metric dimethylarginine (ADMA), homocysteine, phos-
phate, and calcium-phosphate product, are all potential
culprits in uremia (Table 2).
Advanced glycation end products (AGEs)
Both CKD and dialysis treatment are associated with
oxidative and carbonyl stress and, therefore, with an in-
creased microinflammatory status [72]. Inflammation and
oxidative/carbonyl stress damage may act synergistically
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on inducing accelerated atherosclerosis and increasing
cardiovascular morbidity and mortality in CKD [73].
Oxidative stress, nitric oxide (NO), and asymmetric
dimethylarginine (ADMA)
Nitric oxide is a vasodilator compound that partici-
pates in regulation of endothelial function and inhibits
atherosclerotic process [74]. In addition, NO synthesis
can be blocked by endogenous inhibitors, such as ADMA
[75]. Recent clinical studies demonstrated that increased
blood ADMA levels correlate with endothelial dysfunc-
tion and cardiovascular mortality in patients with chronic
kidney disease [76].
Homocysteine
Hyperhomocysteinemia strongly correlates with car-
diovascular disease both in general population and in
uremic patients [77]. Furthermore, the decrease in blood
homocysteine levels in hemodialysis patients rarely
reaches “normal” values of general population [78]. How-
ever, the role of hyperhomocysteinemia as a nonclassic
cardiovascular risk factor for atherosclerosis in chronic
kidney disease patients needs to be better clarified [79].
CARDIOVASCULAR CALCIFICATIONS IN
CKD PATIENTS
Calcification of blood vessel walls occurs frequently
with advanced age, atherosclerosis, and diabetes melli-
tus. Some autopsies [4, 5] and clinical studies [8] have
documented a higher prevalence of coronary plaques in
dialyzed patients compared to the nonuremic population.
In contrast, Sharples et al [80] recently observed that
coronary artery calcification quantified by electron-beam
computed tomography (EBCT) does not correlate with
obstructive coronary lesions detected by angiography in
single arteries in dialysis patients. However, a zero cal-
cification score had a negative predictive value of 87.5%
[80]. In the general population, there was no direct corre-
lation between plaque by angiography and vascular cal-
cification by EBCT. The risk factors contributing to the
higher prevalence of atherosclerotic lesions in chronic
renal failure include high blood pressure, diabetes, dys-
lipidemia, hyperhomocysteinemia, and endothelial dys-
function [81].
Vascular changes in ESRD are associated with in-
creased atherosclerosis, ischemic heart disease, and vas-
cular stiffening [82] In a recent study, London et al [83]
observed that intimal and medial arterial calcification is
common in young and middle-age dialysis patients who
do not have conventional atherosclerotic risk factors.
Moreover, arterial medial calcification increased arterial
stiffness, both strong markers of cardiovascular mortal-
ity clearly associated with months of dialysis and calcium
load [83]. Moreover, left ventricular hypertrophy and
aortic stiffness are major determinants of cardiovascular
mortality in hemodialysis patients, in which aortic pulse
wave velocity (PWV) index can greatly correlate with the
cardiovascular and overall mortality risk. In fact, Blacher
et al [84] demonstrated that aortic PWV index, like age
of dialysis, represents a strong and important predictor of
mortality in end-stage kidney disease patients. Both ac-
celerated atherosclerosis and calcification of arterial in-
tima and media caused arterial stiffness and consequent
hemodynamic changes, with elevated systolic blood pres-
sure [85].
Increases in serum levels of phosphate and calcium-
phosphate product have been associated with arterial
calcification in renal failure, but a clear correlation be-
tween cardiovascular calcification and mortality needs to
be better clarified [86]. Recent evidence demonstrates
that calcium-containing phosphate-binders can increase
calcium load [83]. In patients with CKD there are many
factors involved in the pathogenesis of cardiovascular
disease: hypertension, dyslipidemia, left ventricular hy-
pertrophy, arterial stiffness, inflammation, and hyperho-
mocystenemia [86]. In addition, altered phosphate and
calcium-phosphate product levels may worsen cardio-
vascular events in this population by causing a pro-
gressive increase in calcium deposition in the coronary
arteries and cardiac valves. A study of adolescent and
young adult hemodialysis patients by Goodman et al [15]
noted a correlation between coronary artery calcifica-
tion detected by EBCT and duration of dialysis, serum
phosphorus and calcium-phosphate product levels, and
daily intake of calcium. Another study in 200 hemodialy-
sis patients by Chertow et al [11] showed that sevelamer
attenuated the progression of coronary and aortic cal-
cification better than calcium-based phosphate binders
after 12 months. Subjects treated with sevelamer had
lower serum calcium, total cholesterol, and low-density
lipoprotein (LDL) levels compared to subjects treated
with calcium-based phosphate binders.
Thus, in the past 5 years, several investigators have
demonstrated a potential role of an increased “calcium
load” as a pathogenic mechanism in the development of
vascular calcification. Total body calcium can be quite
positive and contributes to vascular calcification without
overt increases in serum calcium concentrations in pa-
tients undergoing dialysis. Long-term prospective studies
are necessary to address the actual role of calcium over-
load in the etiopathogenesis of vascular calcification and
increased morbidity and mortality due to cardiac events
in CKD.
CONCLUSION
Cardiovascular calcifications are very common in
patients with CKD. The contribution of high serum
phosphate, calcium-posphate product, and PTH levels to
vascular calcification is still incompletely understood. In
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addition to the classic alterations in bone and mineral
metabolism, an active process has been reported in which
vascular cells elicit features of osteoblasts. Multiple fac-
tors in kidney disease, including uremic toxins, were asso-
ciated to increased extraskeletal calcification. However,
prospective, controlled studies are mandatory for proper
elucidation of their relative contribution to cardiovascu-
lar complications in CKD.
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